Lowers the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS). Sold as Zokinvy. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Lonafarnib (sold as Zokinvy), first approved Nov 20, 2020, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Phase I/II Trial of Everolimus in Combination With Lonafarnib in ProgeriaProgeria · Boston Children's Hospital | Phase 1 / Phase 2 | Enrolling by invitation | Oct 19, 2015 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 20, 2020 | ZokinvyNDA 213969 · New molecular entity | Sentynl Theraps Inc | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
